Cullen/Frost Bankers
RIGL icon

Cullen/Frost Bankers’s Rigel Pharmaceuticals RIGL Stock Holding History

Cullen/Frost Bankers’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-107
Closed -$2.89K – 1477
2026
Q1 		$2.89K Sell
107
-1,175
-92% -$39.5K ﹤0.01% 1220
2025
Q4 		$54.9K Buy
1,282
+44
+4% +$1.66K ﹤0.01% 777
2025
Q3 		$35.1K Sell
1,238
-90
-7% -$2.69K ﹤0.01% 821
2025
Q2 		$24.9K Buy
1,328
+852
+179% +$16.2K ﹤0.01% 885
2025
Q1 		$8.56K Buy
476
+74
+18% +$1.5K ﹤0.01% 972
2024
Q4 		$6.76K Buy
+402
New +$7.71K ﹤0.01% 948

Other funds holding RIGL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Soleus Capital Management
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Armistice Capital
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cullen/Frost Bankers's RIGL Position: Q2 2026 in Review

Cullen/Frost Bankers sold out of Rigel Pharmaceuticals (RIGL) in Q2 2026, closing a stake of 107 shares — an estimated $2.89K sold.

Cullen/Frost Bankers first reported a position in RIGL in Q4 2024 and held it in 6 quarters. The position peaked at $54.9K in Q4 2025. 155 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

  • Cullen/Frost Bankers reported no remaining Rigel Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Cullen/Frost Bankers sold 107 Rigel Pharmaceuticals shares in Q2 2026, an estimated $2.89K.
  • Cullen/Frost Bankers first reported a position in Rigel Pharmaceuticals in Q4 2024 and held it in 6 quarters.
  • Cullen/Frost Bankers's Rigel Pharmaceuticals position peaked at $54.9K in Q4 2025.
  • 155 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on Cullen/Frost Bankers's 13F filing for Q2 2026, filed 27 Jul 2026.